Last $89.50 USD
Change Today +1.95 / 2.23%
Volume 50.0
MKGAF On Other Exchanges
Symbol
Exchange
OTC US
Xetra
OTC US
Stuttgart
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

merck kgaa (MKGAF) Snapshot

Open
$89.50
Previous Close
$87.55
Day High
$89.50
Day Low
$89.50
52 Week High
12/30/13 - $90.50
52 Week Low
10/9/13 - $75.00
Market Cap
38.8B
Average Volume 10 Days
70.7
EPS TTM
--
Shares Outstanding
129.2M
EX-Date
05/12/14
P/E TM
--
Dividend
$1.02
Dividend Yield
1.46%
Current Stock Chart for MERCK KGAA (MKGAF)

Related News

No related news articles were found.

merck kgaa (MKGAF) Related Businessweek News

No Related Businessweek News Found

merck kgaa (MKGAF) Details

Merck KGaA, together with its subsidiaries, discovers, develops, manufactures, and markets products in the pharmaceutical and chemical sectors worldwide. It operates through four divisions: Merck Serono, Consumer Health, Performance Materials, and Merck Millipore. The Merck Serono division provides prescription medicines for the treatment of cancer, multiple sclerosis, infertility, growth disorders, cardiovascular, and metabolic diseases and allergies. The Consumer Health division offers over-the-counter pharmaceuticals for mobility and agility, everyday health protection, women’s and children’s health, and cough and cold under the Bion 3, Nasivin, Femibion, Seven Seas, Sangobion, Cebion, Sedalmerck, and Kytta brand names. The Performance Materials division provides specialty chemicals for use in various end products, such as liquid crystals for displays; LED materials for lighting, and OLED materials for lighting and displays; functional materials for solar panels and energy solutions; pigments, active ingredients, and fillers for cosmetics, food, and pharmaceutical products; and pigments and functional materials for coatings, printing, and plastics. The Merck Millipore division offers tools and laboratory chemicals that are used in the research, pharmaceutical and biotechnology industries, and analytical and clinical laboratories. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

39,230 Employees
Last Reported Date: 08/13/14
Founded in 1668

merck kgaa (MKGAF) Top Compensated Officers

Chairman of Executive Board and Chief Executi...
Total Annual Compensation: €5.4M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner, Member of Executive Board an...
Total Annual Compensation: €4.5M
General Partner and Member of Executive Board
Total Annual Compensation: €3.7M
Compensation as of Fiscal Year 2013.

merck kgaa (MKGAF) Key Developments

Merck KGaA Announces Executive Appointments

Merck KGaA announced that E. Merck KG has appointed Stefan Oschmann, 57, to the position of Vice Chairman and Deputy CEO. Concurrently, Bel-n Garijo, 54, has been appointed to the Executive Board to take over leadership for the Pharma business. The management changes will be effective as of January 1, 2015. Oschmann, currently CEO Pharma, will represent Karl-Ludwig Kley, Chief Executive Officer and Chairman of the Executive Board, in his responsibilities. Both will share strategic management functions and represent the company with politicians and international organizations. As a member of the Executive Board, Garijo, currently CEO of Merck's biopharmaceutical division Merck Serono, will take on responsibility for the whole Pharma business, which in addition to Merck Serono comprises Consumer Health, Allergy and Biosimilars.

Sutro Biopharma and Merck KGaA to Partner on Development of Antibody Drug Conjugates

Sutro Biopharma and Merck KGaA announced the collaboration and license agreement to develop antibody drug conjugates (ADCs). ADCs are composed of an antibody linked to a cytotoxic drug. The antibody is thought to specifically target and deliver the cytotoxic drug to the cancer cells. The collaboration will allow the biopharmaceutical division of Merck KGaA to take advantage of Sutro's technology platforms in its oncology programs to develop ADCs for multiple undisclosed targets. Both companies believe that ADCs have the potential for directly targeting cancer cells while safeguarding healthy tissue and will combine Merck KGaA's knowledge about target biology with Sutro's technological and discovery capabilities to jointly develop ADCs. By following a strategic approach of creating partnerships, Merck KGaA and Sutro aim to develop drug candidates that may ultimately address the unmet needs of patients. Under the terms of the agreement, Sutro and Merck KGaA will collaborate to discover and develop multiple ADCs utilizing Sutro's cell-free protein synthesis platforms, Xpress CF(TM) and Xpress CF+(TM). Sutro will be responsible for delivering ADCs for Phase 1 clinical trials. Merck KGaA will be responsible for clinical development and commercialization of any resulting products. Merck KGaA will make an upfront payment to Sutro and will fund certain R&D activities. Sutro is also eligible to receive payments on completion of certain research, development and regulatory milestones potentially totaling approximately EUR 230 million as well as royalties on product sales. Further financial details are not being disclosed.

Merck KGaA Discontinues Clinical Development Program of Tecemotide as Monotherapy in Stage III Non-Small Cell Lung Cancer

Merck KGaA announced that its biopharmaceutical division will discontinue the clinical development program of its investigational MUC1 antigen-specific cancer immunotherapy tecemotide (also known as L-BLP25) as a monotherapy in Stage III non-small cell lung cancer (NSCLC). Therefore, the company decided to discontinue the development of tecemotide as a monotherapy in NSCLC in order to refocus efforts on other promising candidates in pipeline, like anti-PD-L1 antibody MSB0010718C. The company remain committed to developing new treatment options for patients with difficult-to-treat cancers. The company's decision to discontinue the current clinical program in NSCLC, which includes the Phase III START2 and INSPIRE studies, follows recent results from a planned analysis of EMR 63325-009, a randomized, double-blind, placebo-controlled Phase I/II study in Japanese patients with Stage III unresectable, locally advanced NSCLC who had received concurrent or sequential chemoradiotherapy (CRT), with a minimum of two cycles of platinum-based chemotherapy and radiation dose 50 Gy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKGAF:US $89.50 USD +1.95

MKGAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €50.28 EUR +0.07
PPG Industries Inc $202.81 USD -0.35
Seiko Epson Corp ¥5,390 JPY +170.00
Solvay SA €122.60 EUR 0.00
Sherwin-Williams Co/The $220.54 USD +0.68
View Industry Companies
 

Industry Analysis

MKGAF

Industry Average

Valuation MKGAF Industry Range
Price/Earnings 22.7x
Price/Sales 2.6x
Price/Book 2.5x
Price/Cash Flow 4.1x
TEV/Sales 0.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK KGAA, please visit www.merck.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.